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ABSTRACT 
Transcranial direct current stimulation (tDCS) is a form of neurostimulation that has recently regained popularity 
in its experimental use. tDCS utilizes a direct current applied to the scalp via electrodes to induce long-term 
changes to cortical excitability. A series of recent studies and reviews concluded its efficacy as a potential 
treatment for major depressive disorder. However, further research is required to establish effective montages 
and intensities of treatment to promote efficacy while reducing adverse effects. These potential future studies 
should include wider representative samples with more detailed reporting of adverse effects. Until then, this 
perspective piece argues that tDCS should continue to be considered as a potential addition to the therapies 
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Introduction 
Depression is an illness affecting at least 9% of the 
British adult population.1 It led to the loss of 10.4 
million working days in 2012/3.2 Currently, the 
standard treatment regimen involves the use of both 
selective serotonin reuptake inhibitor (SSRI) 
antidepressant drugs3 and psychotherapy.4 
Electroconvulsive therapy is well known to 
practitioners and the public alike as a form of 
psychiatric treatment. Lesser known is transcranial 
direct current stimulation (tDCS), which has yet to be 
adopted in a mainstream clinical setting. tDCS is a 
brain stimulation technique that uses a small direct 
current to stimulate targeted areas of the brain via a 
positive anode and a negative cathode. There has 
been historical interest in this area of research,5 but 
it is only recently that developments have been 
made towards its inclusion in the treatment of 
conditions such as depression and stroke.6 
The first recorded application of a direct current to 
the brain for therapeutic purposes can be found in 
the experiments of Mesmer and Aldini.5 Interest was 
reawakened in the 1960s when it was shown that 
tDCS may affect neuroexcitability and improve 
cognitive performance, but this discovery was 
overlooked due to the development of effective 
psychopharmacy.7 However, long-term treatment 
with psychopharmaceuticals is often associated with 
undesirable side effects and treatment resistance. In 
2001, tDCS was further shown to produce changes 
in cortical neuronal excitability,8 a discovery which 
led to a renewed interest in tDCS and investigation 
into its experimental and potential clinical 
applications.6,7 
As to the mechanisms behind tDCS, the anode is 
thought to produce increased neuronal excitability 
at the targeted site while the cathode is thought to 
decrease it. These excitability changes do not lead 
to the production of an action potential directly but 
alter the probability of a neuron firing.8 
Recent studies have suggested that tDCS is an 
effective therapeutic tool both as a monotherapy 
and in concert with psychopharmaceuticals in 
managing treatment-resistant depression. 9,10 
However, tDCS has yet to be approved by NICE or 
any other governing body for use in a standard 
clinical setting, though guidelines are in 
development.11 This article briefly attempts to justify 
its inclusion in future treatment guidelines. 
  
Current experimental use of tDCS in 
depression 
In current investigations into the use of tDCS 
towards in depression, the anode is placed over the 
left dorsolateral prefrontal cortex (DLPFC) and the 
cathode is placed over lateral aspect of the 
contralateral orbit.9 Underactivity of the DLPFC is 
associated with depression,8 and it is hoped that the 
excitatory activity of the anode can correct this. A 
weak current is passed through the brain, usually 
0.5–2 mA for sessions lasting around 30 minutes.7,9 
Though the standard is several weeks of anodal 
2 mA tDCS applied regularly, different parameters 
are being experimented with to ascertain the 
optimum intensity and montage.12 This produces 
demonstrable changes to neuroexcitability7 and the 
severity of depression.9 Current understanding of 
neuroplasticity highlights that long-term changes in 
neuroexcitability may result from this stimulation. 
These changes and enhancements could last after 
the original stimulus is withdrawn7 and may lead to 
increased spontaneous firing rates. 
Several recent reviews and meta-analyses have 
investigated the use of tDCS in the treatment of 
depression.7,13,14 They concluded that tDCS was 
more effective than sham for the treatment of 
depression, though some results were mixed and 
further randomized controlled trials with larger 
sample sizes and better reporting of side effects are 
needed. 
When compared to pharmacological therapies, 
tDCS may be more effective than SSRIs for the 
treatment of depression. A randomized controlled 
trial investigating the use of tDCS to treat a major 
depressive episode produced a number needed to 
treat (NNT) of 2.6 after 6 weeks.9 Given that the NNT 
of SSRIs is 7,3 this demonstrates how potentially 
effective tDCS could be in the treatment of major 
depressive episodes. In addition to this, studies 
investigating the effects of tDCS in depressed 
subjects treated unsuccessfully with antidepressants 
found improvement.9 Furthermore, reviews of the 
experimental treatment of depression with tDCS 
found that a reduction in depressive symptoms7 and 
higher rates of remission14 were observed in studies 
where the subjects were both taking and not taking 
antidepressants. The greater reductions were 
usually seen in subjects taking antidepressants. 
Finally, a study examining clinical response found 
greater changes in subjects undergoing tDCS in 
combination with antidepressants than in those 
taking antidepressants alone.15 Thus, there is 
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evidence for the clinical use of tDCS, both as an 
adjunct to treatment and as a distal line 
monotherapy for depression and drug-resistant 
depression. 
Potential advantages and disadvantages of 
tDCS 
There are already other forms of brain stimulation 
used in the treatment of severe depression, so what 
are the advantages of tDCS over others? In 
comparison to alternative forms of brain stimulation, 
tDCS is more cost effective,6 easier to use, less 
invasive,7 and has potentially fewer side effects.7 The 
devices used to administer tDCS are smaller and 
more portable so they are easier to store in a clinic 
or as part of a mobile service. 
tDCS is not without its disadvantages: a review of 
adverse effects of tDCS found itching, tingling, and 
headache to be most common.16 However, the 
increased incidence of these adverse effects in 
genuine tDCS compared to sham was not 
statistically significant. This demonstrates an 
advantage over pharmacotherapies, the long-term 
effects of which are undesirable and may impact 
treatment concordance. However, there is currently 
no data on its long-term side effects, if they do exist.  
Transcranial magnetic stimulation (TMS) is an 
additional form of brain stimulation that is another 
potential treatment option. However, TMS is still 
expensive and difficult to utilize,7 with uncertain 
efficacy due to the difficulties inherent in producing 
a sham alternative during studies. 
The Improving Access To Psychological Therapies 
(IAPT) initiative was introduced as a result of the 
Depression Report,4 which highlights that it is more 
cost-effective to provide psychotherapy to treat 
depression and anxiety compared to the number of 
working days lost to these problems. It follows that 
implementing a similar programme with brain 
stimulation (such as tDCS) may have a similar effect. 
tDCS is also thought to be more cost-effective than 
alternative pharmaceutical or neurostimulative 
programmes in treating depression.6 
In the developing world, poor access to healthcare 
and the expense of drugs lead to poor continuity of 
treatment and difficulty maintaining therapeutic 
levels of pharmaceuticals.6 With tDCS, this is less of 
a concern as the device need only be purchased 
once. The provision of, and the resources available 
to, psychiatric services in the developing world are 
in dire need of improvement.6,17 tDCS is a treatment 
which could possibly assist in ameliorating some of 
these concerns. 
Conclusion and summary 
Recently, many major pharmaceutical companies 
have either reduced funding of their research into 
psychiatric treatments or closed their departments 
altogether,18 citing poor financial returns in these 
areas of research.  Thus, there are fewer new 
treatments being developed that are likely to 
improve or contribute to psychiatric practice in the 
near future. With this in mind, it is important to 
continue investigating further treatment options if 
we are to continue to help a population of patients 
that is predicted to increase. Research should be 
focused on cost-effective, accessible treatments 
that produce viable results. These treatments could 
be used to combat the growing prevalence of 
depression worldwide and the difficulties of 
managing it in the developing world. With evidence 
suggesting its efficacy, tDCS could be considered 
one of those potential treatments. 
tDCS is still in its experimental stages and much 
needs to be done to determine protocols for 
efficient clinical administration, such as further 
research into optimal current intensity and electrode 
placement. In addition to this, further data on side 
effects need to be researched, both to reduce short-
term adverse effects and to investigate the 
occurrence of long-term adverse effects. Once 
these concerns are alleviated, tDCS could be made 
available for the management of depression, in 
addition to or as an adjunct to current treatments. 
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What is known already: What this study adds/ highlights: 
•   Transcranial direct current stimulation (tDCS) is 
an experimental form of neurostimulation which 
has been demonstrated to produce changes in 
cortical excitability.  
•   It is thought that these changes translate into 
alterations of behaviour and may help alleviate 
depression. 
•   Reviews examining the efficacy of tDCS in the 
treatment of depression are hopeful, but larger 
studies with better reporting of side effects 
needs to be carried out. Also, an accepted 
protocol and montage for the administration of 
tDCS needs to be clarified before tDCS can be 
approved as an appropriate therapy.  
•   A supportive argument for the continuing 
investigation of tDCS as a clinical tool for the 
treatment of depression. 
•   A commentary on the current state of treatment 
development in psychopharmacology, 
mentioning its stagnation, the limited 
accessibility of treatment in resource-poor 
countries, and the need to develop new 
therapies. 
•   Contrasting tDCS with current therapies and 
discussing how it may solve the problems 
mentioned above. 
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